| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2017-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c06fccf811afca3880b9fecf0d1f843
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6061bf01e056edf1a59e80e8a5fc3d3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cfe07e025b21e74e14ee9511aea7afd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_997eab00bebe758a81b5bcfc7f33bca3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4319456f671fde9a4db4dd1b7aa2088e |
| publicationDate |
2019-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190066026-A |
| titleOfInvention |
Anti-HER2 Antibody-Drug Conjugate Treatment of Metastatic Carcinoma |
| abstract |
Formula as an effective treatment for HER2 expressing cancer resistant or refractory to the existing anti-HER2 about: - (succinimide-3-yl -N) -CH 2 CH 2 CH 2 CH 2 CH 2 -C (= O) Linker and drug represented by -GGFG-NH-CH 2 -O-CH 2 -C (═O) - (NH-DX) and an anti-HER2 drug conjugated with an anti- The present invention provides a therapeutic agent and a therapeutic method for HER2 expressing cancer resistant or refractory. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022075509-A1 |
| priorityDate |
2016-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |